The stock of Amphastar Pharmaceuticals Incorporated (NASDAQ:AMPH) registered a decrease of 10.27% in short interest. AMPH’s total short interest was 1.72 million shares in September as published by FINRA. Its down 10.27% from 1.92 million shares, reported previously. With 534,900 shares average volume, it will take short sellers 3 days to cover their AMPH’s short positions. The short interest to Amphastar Pharmaceuticals Incorporated’s float is 4.87%. The stock decreased 2.66% or $0.49 during the last trading session, hitting $17.91. About 530,941 shares traded hands or 14.94% up from the average. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has risen 67.12% since February 8, 2016 and is uptrending. It has outperformed by 50.63% the S&P500.
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $819.25 million. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. It has a 58.94 P/E ratio. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients products.
The institutional sentiment increased to 2.1 in 2016 Q2. Its up 0.43, from 1.67 in 2016Q1. The ratio improved, as 7 funds sold all Amphastar Pharmaceuticals Inc shares owned while 23 reduced positions. 19 funds bought stakes while 44 increased positions. They now own 15.47 million shares or 11.85% more from 13.83 million shares in 2016Q1.
Eam Investors Llc holds 0.6% of its portfolio in Amphastar Pharmaceuticals Inc for 246,805 shares. Essex Investment Management Co Llc owns 105,239 shares or 0.28% of their US portfolio. Moreover, Endurant Capital Management Lp has 0.26% invested in the company for 48,825 shares. The California-based Menta Capital Llc has invested 0.2% in the stock. Charlemagne Capital Ltd, a Isle Of Man-based fund reported 14,671 shares.
Out of 4 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Amphastar Pharmaceuticals has been the topic of 6 analyst reports since November 13, 2015 according to StockzIntelligence Inc. Needham maintained the stock on May 10 with “Buy” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.